Asian Pacific Journal of Cancer Prevention

  • 제13권5호
  • /
  • Pages.1935-1941
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey

  • Durnali, Ayse (Medical Oncology Department of Dr A.Y.Ankara Oncology Training and Research Hospital) ;
  • Tokluoglu, Saadet (Medical Oncology Department of Guven Hospital) ;
  • Ozdemir, Nuriye (Medical Oncology Department of Ankara Numune Training and Research Hospital) ;
  • Inanc, Mevlude (Medical Oncology Department of Erciyes University Faculty of Medicine) ;
  • Alkis, Necati (Medical Oncology Department of Dr A.Y.Ankara Oncology Training and Research Hospital) ;
  • Zengin, Nurullah (Medical Oncology Department of Ankara Numune Training and Research Hospital) ;
  • Sonmez, Ozlem Uysal (Medical Oncology Department of Dr A.Y.Ankara Oncology Training and Research Hospital) ;
  • Kucukoner, Mehmet (Medical Oncology Department of Dicle University Faculty of Medicine) ;
  • Anatolian Society of Medical Oncology (ASMO), Anatolian Society of Medical Oncology (ASMO) (Anatolian Society of Medical Oncology (ASMO))
  • 발행 : 2012.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Introduction: Uterine sarcomas are a group of heterogenous and rare malignancies of the female genital tract and there is a lack of consensus on prognostic factors and optimal treatment. Objective and Methodology: To perform a retrospective evaluation of clinicopathological characteristics, prognostic factors and treatment outcomes of 93 patients with uterine sarcomas who were diagnosed and treated at 4 different centers from November 2000 to October 2010. Results: Of the 93 patients, 58.0% had leiomyosarcomas, 26.9% malignant mixed Mullerian tumors, 9.7% endometrial stromal sarcomas, and 5.4% other histological types. According to the last International Federation of Gynecology and Obstetrics (FIGO) staging, 43.0% were stage I, 20.4% were stage II, 22.6% were stage III and 14.0 % were stage IV. Median relapse free survival (RFS) was 20 months (95% confidence interval (CI), 12.4-27.6 months), RFS after 1, 2, 5 years were 66.6%, 44.1%, 16.5% respectively. Median overall survival (OS) was 56 months (95% CI, 22.5-89.5 months), and OS after 1, 2, 5 years was 84.7%, 78%, 49.4% respectively. Multivariate analysis showed that age ${\geq}60$ years and high grade tumor were significantly associated with poor OS and RFS; patients administered adjuvant treatment with sequential chemotherapy and radiotherapy had longer RFS time. Among patients with leiomyosarcoma, in addition to age and grade, adjuvant treatment with sequential chemotherapy and radiotherapy after surgery had significant effects on OS. Conclusion: Uterine sarcomas have poor progrosis even at early stages. Prognostic factors affecting OS were found to be age and grade.

키워드

참고문헌

  1. Ali S, Wells M (1993). Mixed müllerian tumors of the uterine corpus: a review. Int J Gynecol Cancer, 3, 1-11. https://doi.org/10.1046/j.1525-1438.1993.03010001.x
  2. Benito V, Lubrano A, Arencibia O, et al (2009). Clinicopathologic analysis of uterine sarcomas from a single institution in the Canary Islands. Int J of Gynecology & Obstetrics, 107,44-9. https://doi.org/10.1016/j.ijgo.2009.05.020
  3. Benoit L, Arnould L, Cheynel N, et al (2005). The role of surgery and treatment trends in uterine sarcoma. Eur J Surg Oncol, 31, 434-42. https://doi.org/10.1016/j.ejso.2005.01.010
  4. Chavenic L, Deniaud E, Plancher C, et al (1999). Uterine sarcomas: The Curie Institute experience. Prognosis factors and adjuvant treatments. Gynecol Oncol, 72, 232-7. https://doi.org/10.1006/gyno.1998.5251
  5. D'Angelo E, Prat J (2010). Uterine sarcomas: A review. Gynecol Oncol, 116, 131-9. https://doi.org/10.1016/j.ygyno.2009.09.023
  6. Echt G, Jepson J, Steel J, et al (1990). Treatment of uterine sarcomas. Cancer, 66, 35-9. https://doi.org/10.1002/1097-0142(19900701)66:1<35::AID-CNCR2820660108>3.0.CO;2-V
  7. Einstein MH, Klobocista M, Hou JY, et al (2012). Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecol Oncol, 124, 26-30. https://doi.org/10.1016/j.ygyno.2011.10.008
  8. El Husseiny G, Al Bareedy N, Mourad WA, et al (2002). Prognostic factors and treatment modalities in uterine sarcoma. Am J Clin Oncol, 25, 256-60. https://doi.org/10.1097/00000421-200206000-00010
  9. Gaducci A, Cosio S, Romanini A, Genazzani AR (2008). The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol, 65, 129-42. https://doi.org/10.1016/j.critrevonc.2007.06.011
  10. George M, Pejovic MH, Kramar A (1986). Uterine sarcomas: prognostic factors and treatment modalities- study on 209 patients. Gynecol Oncol, 24, 58-67. https://doi.org/10.1016/0090-8258(86)90008-9
  11. Ghaemmaghami F, Zarchi MK, Gilani MM, et al (2008). Uterine sarcoma: Clinicopathological characteristics, treatment and outcome in Iran. APJCP, 9, 421-6.
  12. Hempling RE, Piver MS, Baker TR (1995). Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin(adriamycin) and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective tiral. Am J Clin Oncol, 18, 282-6. https://doi.org/10.1097/00000421-199508000-00002
  13. Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A (2008). Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001. Gynecol Oncol, 111, 74-81. https://doi.org/10.1016/j.ygyno.2008.06.002
  14. Kokawa K, Nishiyama K, Ikeuchi M, et al (2006). Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990-2003). Int J Gynecol Cancer, 16, 1358-63. https://doi.org/10.1111/j.1525-1438.2006.00536.x
  15. Livi L, Paiar F, Shah N, et al (2003). Uterine sarcoma: twentyseven years of experience. Int J Radiat Oncol Biol Phys, 57, 1366-73. https://doi.org/10.1016/S0360-3016(03)00750-8
  16. Major FJ, Blessing JA, Silverberg SG, et al (1993). Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer, 71, 1702-9. https://doi.org/10.1002/cncr.2820710440
  17. Matoda M, Takeshima N, Nomura H, et al (2011). The treatment of uterine leimyosarcoma: clinical outcomes of 18 cases and the efectiveness of chemotherapy. Eur J Gynaecol Oncol, 32, 647-50.
  18. Menczer J, Levy T, Piura B, et al (2005). A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol, 97, 166-70. https://doi.org/10.1016/j.ygyno.2004.12.006
  19. Odunsi K, Moneke V, Tammela J, et al (2004). Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long term follow up. Int J Gynecol Cancer, 14, 659-64. https://doi.org/10.1111/j.1048-891X.2004.14420.x
  20. Olah KS, Dunn JA, Gee H (1992). Leimyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynecol, 99, 590-4. https://doi.org/10.1111/j.1471-0528.1992.tb13827.x
  21. Olah KS, Gee H, Blunt S, et al (1991). Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer, 27, 1095-9. https://doi.org/10.1016/0277-5379(91)90300-3
  22. Omura GA, Bleesing JA, Major F, et al (1985). A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol, 3,1240-5. https://doi.org/10.1200/JCO.1985.3.9.1240
  23. Park J-Y, Kim D-Y, Suh D-S, et al (2008). Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol, 134, 1277-87. https://doi.org/10.1007/s00432-008-0422-2
  24. Pautier P, Genestie C, Rey A, et al (2000). Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer, 88, 1425-31. https://doi.org/10.1002/(SICI)1097-0142(20000315)88:6<1425::AID-CNCR21>3.0.CO;2-3
  25. Peters WA 3rd, Kumar NB, Fleming WP, Morley GW (1984). Prognostic features of sarcomas and mixed tumors of the endometrium. Obstet Gynecol, 63, 550-6.
  26. Prat J (2009). FIGO staging for uterine sarcomas. Int J Gynecol Obstet, 104, 177-8. https://doi.org/10.1016/j.ijgo.2008.12.008
  27. Rovirosa A, Ascaso C, Ordi J, et al (2002). Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. Int J Radiat Oncol Biol Phys, 52, 1320-9. https://doi.org/10.1016/S0360-3016(01)02808-5
  28. Sagage S, Yamashita K, Ishioka S, et al (2004). Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology, 67, 33-9. https://doi.org/10.1159/000080283
  29. Salazar OM, Dunne ME (1980). The role of radiation therapy in the management of uterine sarcomas. Int J Radiat Oncol Biol Phyis, 6, 899-902. https://doi.org/10.1016/0360-3016(80)90334-X
  30. Sartori E, Bazzurini L, Gadducci A, et al (1997). Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol, 67, 70-5. https://doi.org/10.1006/gyno.1997.4827
  31. Schwartz SM, Thomas DB (1989). A case-control study of risk factorsfor sarcomas of the uterus. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer, 64, 2487-92. https://doi.org/10.1002/1097-0142(19891215)64:12<2487::AID-CNCR2820641214>3.0.CO;2-K
  32. Sharma DN, Rath GK, Kumar S, et al (2011). Clinical outcome of patients with uterine sarcomas. J Cancer Res Ther, 7, 270-4. https://doi.org/10.4103/0973-1482.87011
  33. Sleijfer S, Seynaeve C, Verweij (2007). Gynaecological sarcomas. Curr Opin Oncol, 19, 492-6. https://doi.org/10.1097/CCO.0b013e3282748eaa
  34. Sutton G, Kauderer J, Carson LF, et al (2005). Gynecologic Oncology Group. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol, 96, 630-4. https://doi.org/10.1016/j.ygyno.2004.11.022
  35. Tavassoli FA, Devilee P (2003). Pathology and Genetics of Tumors of the Breast and Female Genital Organs. World Health Organization Classification of Tumors. Lyon, France: IARC Pres
  36. Temkin SM, Hellmann M, Lee YC, Abulafia O (2007). Earlystage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer, 17, 215-9. https://doi.org/10.1111/j.1525-1438.2006.00762.x
  37. Tsikouras P, Liberis V, Galazios G, et al (2008). Uterine sarcoma: a report of 57 cases over a16-year period analysis. Eur J Gynecol Oncol, 29, 129-34.
  38. Van Nagell JR Jr, Hanson MB, Donaldson ES, Gallion HH (1986). Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study. Cancer, 57, 1451-4. https://doi.org/10.1002/1097-0142(19860415)57:8<1451::AID-CNCR2820570802>3.0.CO;2-Y
  39. Wolfson AH, Wolfson DJ, Sittler SY, et al (1994). A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol, 52, 56-62. https://doi.org/10.1006/gyno.1994.1011

피인용 문헌

  1. Diagnostic Performance of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Imaging in Uterine Sarcomas vol.23, pp.8, 2013, https://doi.org/10.1097/IGC.0b013e3182a20e18
  2. Immunohistochemical Survey of Mismatch Repair Protein Expression in Uterine Sarcomas and Carcinosarcomas vol.33, pp.5, 2014, https://doi.org/10.1097/PGP.0b013e31829ff239
  3. Prognostic Factors, Treatment and Outcome in a Turkish Population with Endometrial Stromal Sarcoma vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.881
  4. CD146 as an adverse prognostic factor in uterine sarcoma vol.20, pp.1, 2015, https://doi.org/10.1186/s40001-015-0160-2
  5. Is open surgery the solution to avoid morcellation of uterine sarcomas? A systematic literature review on the effect of tumor morcellation and surgical techniques vol.292, pp.3, 2015, https://doi.org/10.1007/s00404-015-3664-7
  6. Uterine Sarcoma: The Indian Scenario vol.6, pp.3, 2015, https://doi.org/10.1007/s13193-015-0433-9
  7. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.1759
  8. Animal Models for Tuberculosis in Translational and Precision Medicine vol.8, pp.1664-302X, 2017, https://doi.org/10.3389/fmicb.2017.00717
  9. Impact of adjuvant treatment on oncologic outcomes inpatients with stage I leiomyosarcoma of the uterus vol.47, pp.13036165, 2017, https://doi.org/10.3906/sag-1603-135